An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.

Inclusion Criteria Patients must have: HIV-1 seropositivity. CD4 counts >= 550 cells/ml. NOTE: If a patient's CD4 count is 550 to 600 cells/ml, the patient must either rescreen within 30 days for Study 806 or wait 6 months before entering the expanded access program. Patient must have failed or been intolerant to other comparable or alternative marketed therapies or must not be a candidate for such therapies. Patient must not meet inclusion criteria for other Remune trials. Patient must have laboratory tests within specified limits. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Clinically significant cardiac, hepatic, renal or gastrointestinal dysfunction. Current participation in a Remune study. Concurrent Medication: Excluded: Use of any immune-modulating drugs. Induction therapy or initiation of new treatment regimen for an AIDS-defining condition. Current participation in a Remune study. Patients with any of the following prior conditions are excluded: Previous participation in a Remune study. Prior Medication: Excluded: Previous participation in a Remune study. Excluded within 30 days of study entry: Use of any immune-modulating drugs. Induction therapy or initiation of new treatment regimen for an AIDS-defining condition within 30 days of Day 1 visit.